For anyone in Wells searching for CJC-1295, the foundational reality is that this compound moves through online research channels. This concentration of supply in online vendors is a genuine benefit for researchers — top vendors differentiate through analytical documentation in ways no local retailer can match. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. This guide walks Wells researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Wells researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Quality CJC-1295 sourcing begins with a useful first test: does this vendor publish batch-specific COAs proactively? Suppliers that publish proactively are demonstrating research-grade standards. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger dangerous inflammatory cascades even at minute levels. Signs of a credible vendor beyond COA quality: established track record of at least two years, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Wells
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is educational. Temperature excursions — even brief warming above recommended storage temperature — can partially degrade CJC-1295 without visible changes; always verify cold chain was maintained during shipping. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results reported in endotoxin units per mg or mL and verify they are within the acceptable range for your research context. PubMed and bioRxiv represent the most comprehensive research databases for CJC-1295 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
